ABBV · sample dossier
ABBVIE INC.
60/100
Stale StatementsGenerated Oct 24, 2026 · 10:00 AM UTC · 1 hour ago
This copy is frozen (Oct 24). Sign in to run the same work — filings, valuation, bull and bear, sources — on any US stock or ETF, in about 90 seconds.
Run a fresh dossierABBV
EquityABBVIE INC. · XNYS
Decision context
Recommendation
A mixed picture — no strong reason to buy or sell right now.
AlphaDog Fair Value
Market context
Snapshot returns at report publication
1 month
+7.7%
3 months
+11.2%
6 months
+43.7%
1 year
+24.9%
At a Glance
A very large company is riding a strong uptrend at premium pricing.
Top Holders
As of Jun 30, 2026Financial trajectory
Financial Performance
Executive thesis & key metrics
Executive Thesis
AbbVie Inc. (ABBV) is a $504.76B market-cap pharmaceutical manufacturer trading at $285.64 with a 72.8% TTM gross margin and $10.28 in TTM FCF/sh [c1, c2].
Key Metrics to Watch
What changed recently
Why this rating
The latest quarter is more than 100 days old, so this stays a Hold.
Data through
Stale StatementsSep 30, 2026
A newer quarter has been reported and is not in these statements.
Momentum 90/100 — 1Y return 25%.
Re-evaluate if
- Net margin falls below 7.8% (was 9.8%)
- YoY revenue growth slows below 10.2% or TTM gross margin dips below 72.8% [c2, c3].
Trim / reconsider if
- ROA falls below 6.8% (was 10.5%)
- TTM FCF/sh declines below $10.28 while TTM P/E remains at or above 80.46.
Think of these dollars as a map of our value estimate for Hold — helpful context, not a reason to override the view.
A Calmer Look · Devil's Advocate
The consensus Hold posture balances surface-level metrics while failing to interrogate the massive accounting chasm between AbbVie's 72.8% gross margin and its compressed 9.8% net margin.
May be overlooked
The 63-percentage-point collapse from a 72.8% TTM gross margin to a 9.8% TTM net margin is brushed aside as generic 'non-operating expenses' without analyzing the recurring cash versus non-cash nature of pharmaceutical amortization and legal reserves.
The unavailability of Debt/Equity and Price/Book ratios in the dataset is treated as a benign reporting gap, ignoring the possibility of negative or near-zero book value resulting from historical debt-funded M&A.
The Bear Advocate mentions the 'Humira patent cliff' in passing, yet neither the synthesis report nor the bull case quantifies the specific revenue erosion of Humira versus the replacement rate of newer immunology assets within the $31,992M six-month revenue total.
Expectations look stretched
The Bull claim that 290.4% YoY EPS growth ($2.03 vs. $0.52) and 420.5% QoQ EPS growth prove 'strong operating leverage' is invalid because it stems primarily from lapping $823M of prior-year IPR&D charges compared to $291M in the stale Q2 2026 period.
The Judge's ruling that the strongest bull argument is a 43.7% 6-month and 24.9% 1-year price return relies purely on trend extrapolation rather than fundamental moat durability.
Assuming the Altman Z-Score of 3.00 guarantees balance sheet safety is premature when the exact TTM Debt/Equity ratio is N/A and the score is heavily buoyed by the $504.76B market capitalization component.
YoY revenue growth slows below 10.2% or TTM gross margin dips below 72.8% [c2, c3].
YoY revenue growth slows below 10.2% or TTM gross margin dips below 72.8% [c2, c3].
Monitor These Triggers
3 Checkpoints · Next PrintYoY revenue growth versus the 10.2% baseline and TTM net margin versus 9.8% to evaluate whether earnings expansion can compress the 80.46 TTM P/E [c2, c3].
Go deeper
For learning and research only — not investment advice. AlphaDog doesn’t hold stocks and isn’t your financial advisor.
Run the next one yourself.
You just read a full ABBV dossier — scored verdict, valuation, and both sides, with sources. Sign in to run that on a name you hold, on current filings. A free account includes 10 credits a week, 1 per fresh run.